The efficacy of deucravactinib in treating plaque psoriasis is attributed to the selective inhibition of TYK2, a downstream mediator of proinflammatory signalling pathways critical to psoriasis.3 This evidence concerns the gene TYK2 and psoriasis vulgaris.